Is MiMedx Group, Inc. overvalued or undervalued?

As of 30 July 2025, the valuation grade for MiMedx Group, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company is fairly valued based on its current metrics. Key ratios include a P/E ratio of 24, an EV to EBITDA of 14.64, and a Price to Book Value of 4.75. In comparison, peer companies such as LeMaitre Vascular, Inc. exhibit a higher P/E ratio of 49.77, while Stevanato Group SpA shows an even higher P/E of 51.03, suggesting that MiMedx is relatively less expensive than some of its peers.
Despite the fair valuation, MiMedx has underperformed against the S&P 500 in several timeframes, notably with a year-to-date return of -25.68% compared to the S&P 500's 12.22%. However, over a three-year period, MiMedx has delivered a substantial return of 119.33%, outperforming the S&P 500's 70.41%. This mixed performance underscores the importance of considering both current valuation metrics and historical performance when assessing the company's investment potential.